TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01388959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab [MabThera/Rituxan]
Description: 375 mg/m2 intravenously once a week for 4 weeks
Study: NCT02769507

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DC Stimulator PLUS (NeuroConn)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: DC Stimulator PLUS (NeuroConn)
Study: NCT00111007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: Sorafenib, 400 mg po (per os), 2 tablets (200 mg each) bid Study Days 2-19

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin/Paclitaxel
Description: Paclitaxel (225 mg/m\^2 iv) and Carboplatin (AUC 6 iv) on Study Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin/Paclitaxel
Description: Paclitaxel (225 mg/m\^2 iv) and Carboplatin (AUC 6 iv) on Study Day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo, 2 tablets bid Study Days 2-19
Study: NCT02198820

Intervention type: DRUG
Intervention: General Anesthesia
Description: General anesthesia with proposal, rocuronium and sufentanil

Intervention type: DRUG
Intervention: Loco Regional Anesthesia
Description: Loco Regional Anesthesia with marcaine
Study: NCT02989259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: apatinib 500mg p.o. qd
Study: NCT05588765

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neck stretching exercises
Description: Neck stretching exercises towards lateral flexion, ipsilateral flexion and rotation and towards flexion each for 30 sec and repeated 2-3 times

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neck stretching exercises
Description: Neck stretching exercises towards lateral flexion, ipsilateral flexion and rotation and towards flexion each for 30 sec and repeated 2-3 times
Study: NCT01170988

Intervention type: PROCEDURE
Group type: OTHER
Intervention: T-Graft
Description: T-Graft
Study: NCT04551456

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravenous infusion human umbilical Wharton's jelly-derived mesenchymal stem Cell or placebo PBS
Description: Randomised, Double-blind, Placebo-controlled, Intravenous Infusion HumanWharton' Jelly-derived Mesenchymal Stem Cells in Patients With Coronary Artery Disease

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous infusion human umbilical Wharton's jelly-derived mesenchymal stem Cell or placebo PBS
Description: Randomised, Double-blind, Placebo-controlled, Intravenous Infusion HumanWharton' Jelly-derived Mesenchymal Stem Cells in Patients With Coronary Artery Disease

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravenous infusion human umbilical Wharton's jelly-derived mesenchymal stem Cell or placebo PBS
Description: Randomised, Double-blind, Placebo-controlled, Intravenous Infusion HumanWharton' Jelly-derived Mesenchymal Stem Cells in Patients With Coronary Artery Disease
Study: NCT02436343

Intervention type: OTHER
Intervention: echocardiogram
Description: At each echocardiographic evaluation, the investigator will obtain the following parameters:~Left ventricular internal dimensions at end diastole Left ventricular posterior wall thickness Left ventricular end systolic stress Left ventricular fractional shortening Velocity of circumferential shortening Left ventricular mass Contractility and indices of preload Stroke volume

Intervention type: OTHER
Intervention: echocardiogram
Description: At each echocardiographic evaluation, the investigator will obtain the following parameters:~Left ventricular internal dimensions at end diastole Left ventricular posterior wall thickness Left ventricular end systolic stress Left ventricular fractional shortening Velocity of circumferential shortening Left ventricular mass Contractility and indices of preload Stroke volume
Study: NCT04220515

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Poliomyelitis Vaccine Made From Sabin Strain
Description: Type I D antigen 30DU;Type II D antigen 32DU;Type III D antigen 45 DU
Study: NCT03970577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Two injections of Rituximab (375mg/m2) separated by one week (one at time of randomization and the other one week after) and definitive withdrawal of steroid at the time of second injection of Rituximab (for a total steroids exposure of 9 weeks)
Study: NCT04228068

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional care
Description: The control group will receive the usual care provided by the healthcare system.
Study: NCT01016366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AA24493
Description: Vials with solution for i.v. injection. 325mcg Lu AA24493 dosed 3 times per week for two weeks. Vials will be supplied in concentrations ready for injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vials with solution for i.v. injection. Placebo dosed 3 times per week for two weeks.
Study: NCT03856216

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inotuzumab Ozogamicin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inotuzumab Ozogamicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Given IV
Study: NCT03970577

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: exclusive oral steroid therapy (progressively tapered with the same procedure for all patients) for a total exposure of 24 weeks (taking into account the initial oral steroid therapy administered during 8 weeks in addition with the oral steroid treatment given after randomization). Each patient will be followed up until 18 months after randomization.
Study: NCT01364012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered at 15 mg/kg IV on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered at area under the plasma concentration-time curve (AUC) 6.0 IV on Day 1 of each 3-week cycle, up to 6 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin will be administered at area under the plasma concentration-time curve (AUC) 6.0 IV on Day 1 of each 3-week cycle, up to 6 cycles.
Study: NCT00615927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate & Hydroxyurea
Description: Imatinib administered orally on daily. Imatinib is local irritant \& must be taken in sitting position; mini of 2hrs should be allowed between last drug intake \& going to bed. Imatinib doses 400mg/600mg administered once daily, whereas daily doses of 800mg/\> administered as equally divided dose taken twice day. Dose for imatinib: Pts not receiving p450-inducing antiepileptic drugs: 400 mg/day. Pts receiving p450-inducing antiepileptic drugs: 500 mg twice day. It is recommended that pts take their prescribed imatinib mesylate at same time that they take their prescribed hydroxyurea, however, 30-60min interval between agents is acceptable if required for practical/other compliance issues.~Hydroxyurea administered orally twice day. Dosing will begin on day 1 of cycle 1 \& continue daily. Drug is approximately 80 percent bioavailable. Dose will be 500mg twice day for all pts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate & Hydroxyurea
Description: Imatinib administered orally on daily. Imatinib is local irritant \& must be taken in sitting position; mini of 2hrs should be allowed between last drug intake \& going to bed. Imatinib doses 400mg/600mg administered once daily, whereas daily doses of 800mg/\> administered as equally divided dose taken twice day. Dose for imatinib: Pts not receiving p450-inducing antiepileptic drugs: 400 mg/day. Pts receiving p450-inducing antiepileptic drugs: 500 mg twice day. It is recommended that pts take their prescribed imatinib mesylate at same time that they take their prescribed hydroxyurea, however, 30-60min interval between agents is acceptable if required for practical/other compliance issues.~Hydroxyurea administered orally twice day. Dosing will begin on day 1 of cycle 1 \& continue daily. Drug is approximately 80 percent bioavailable. Dose will be 500mg twice day for all pts.
Study: NCT00183170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: Participants report for their first dosing night where they receive several alcohol/beer drinks sufficient to raise their BrAC to 0.10 g%. Participants are breath-tested after completing their required dose. Participants return in a week for the 2nd session and receive placebo drinks. Participants are breath-tested after completing their placebo drinks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: Participants report for their first dosing night where they receive several alcohol/beer drinks sufficient to raise their BrAC to 0.10 g%. Participants are breath-tested after completing their required dose. Participants return in a week for the 2nd session and receive placebo drinks. Participants are breath-tested after completing their placebo drinks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants report for their first night where they receive several placebo drinks. Participants are breath-tested after completing their placebo drinks. Participants return in a week for the 2nd session and receive alcohol drinks sufficient to raise their BrAC to 0.10 g%. Participants are breath-tested after completing their required dose.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants report for their first night where they receive several placebo drinks. Participants are breath-tested after completing their placebo drinks. Participants return in a week for the 2nd session and receive alcohol drinks sufficient to raise their BrAC to 0.10 g%. Participants are breath-tested after completing their required dose.
Study: NCT01364012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered at 175 milligrams per square meter (mg/m\^2) IV on Day 1 of each 3-week cycle, up to 6 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel will be administered at 175 milligrams per square meter (mg/m\^2) IV on Day 1 of each 3-week cycle, up to 6 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Bevacizumab matching placebo will be administered IV on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity.
Study: NCT01656109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: boosted atazanavir (ATV/r)
Description: ATV/r will be taken orally once daily with food plus standard dose of 2 NRTIs according to Thai National HIV treatment guideline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: boosted atazanavir (ATV/r)
Description: ATV/r will be taken orally once daily with food plus standard dose of 2 NRTIs according to Thai National HIV treatment guideline
Study: NCT04246411

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided determination of cuffless RAE tube depth
Description: 1. Measurement of Carina-T2 mid-vertebra length from preoperative Cheat PA~2. Ultrasound-guided detection of endobronchial intubation depth by loss of lung sliding sign in the left lung field.~3. Withdrawal of the cuffless RAE tube using the Carina-T2 mid-vertebra length for optimal positioning

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Auscultation-guided determination of cuffless RAE tube depth
Description: 1. Measurement of Carina-T2 mid-vertebra length from preoperative Cheat PA~2. Auscultation-guided detection of endobronchial intubation depth by loss of breathing sound in the left lung field~3. Withdrawal of the cuffless RAE tube using the Carina-T2 mid-vertebra length for optimal positioning
Study: NCT03564015

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smartphone app
Description: Apple or Android app to provide education to guide functional recovery and allow recording of pain, management, and functional outcome using the Activities Scale for Kids performance version (ASKp) at home

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Paper handout
Description: Paper handout to guide functional recovery. Also includes a version of the smartphone app described above that only allows recording of pain, functional outcome, and management at home.
Study: NCT01187511

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK561679
Description: Verucerfont is a corticotropin releasing hormone receptor 1 (CRF1) antagonist.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is an inactive tablet design to look exactly like GSK561679
Study: NCT01353586

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nMARQ™ System
Description: The nMARQ™ System is indicated for catheter-based electrophysiological mapping for the treatment of drug refractory recurrent symptomatic paroxysmal atrial fibrillatioon.
Study: NCT03187639

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FFRct
Description: In the test group all patients who are eligible for CTA will undergo CTA as their default test. Those patients with any coronary stenosis of equal or \> 40% data in at least one major epicardial vessel of stentable/graftable diameter will be referred for FFRct. (NB Lesions in distal vessels or vessels of a diameter not suitable for stenting/grafting will not qualify for FFRct if there are no other more significant lesions). In patients in whom FFRct analysis is performed, FFR will be derived for all vessels. The data derived from this test will determine their management strategy. The patients in this arm will not follow the NICE guideline algorithm. Those patients randomised to FFRct with contraindications for CTA will be asked to take part in a trial registry.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: All patients in the standard care group will be assessed according to their current conventional pathways that are based upon NICE guidelines for Chest Pain of Recent Onset. The trial will encourage the routine and standard assessment and management of all patients at these sites... (anticipated outcomes include ETT, stress echo, stress MR, nuclear perfusion, CTA, CT calcium, invasive CA, reassurance), in accordance with the local application of the NICE guideline for chest pain of recent onset.
Study: NCT04785846

Intervention type: DEVICE
Intervention: Percutaneous Coronary Intervention
Description: Percutaneous Coronary Intervention
Study: NCT03856216

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV and PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV and PO
Study: NCT03928795

Intervention type: PROCEDURE
Intervention: elective caesarean section
Description: elective caesarean section

Intervention type: PROCEDURE
Intervention: elective caesarean section
Description: elective caesarean section
Study: NCT01453010

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-directed Upper Limb SaeboFlex Training
Description: Participants undergo a 12 week self directed upper limb training programme with the SaeboFlex upper limb orthosis. Training consists of a maximum of 3 x 45 minute sessions a day.~Participants are closely monitored at least once a week by a saebo-trained therapist.
Study: NCT01391624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flaxseed oil
Description: 3 g (3 capsules/day) of flax oil for a period of 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paraffin + # 2 dye
Description: 3 capsules of mineral oil (ineffective) for 8 weeks.
Study: NCT04477161

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone Ester Elite endurance Nutrition Drink
Description: Subjects will take one bottle four times daily for four weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stool Sample
Description: Subjects will provide a stool sample at 2 timepoints.
Study: NCT00005961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: O6-benzylguanine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmustine
Study: NCT02325414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: Intravenous infusion of zoledronic acid 5 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo (saline) infusion to match zoledronic acid
Study: NCT04452019

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of standard standing frame
Description: Two training sessions in a standard standing frame, max 30 min. pr. session

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Use of standard standing frame
Description: Two training sessions in a standard standing frame, max 30 min. pr. session

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of a new device; Innowalk Pro
Description: Two training sessions in Innowalk Pro, max 30 min pr. session

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Use of a new device; Innowalk Pro
Description: Two training sessions in Innowalk Pro, max 30 min pr. session
Study: NCT03231852

Intervention type: OTHER
Intervention: Survey
Description: Attitudes and Randomized Trial Questionnaire (ARTQ), Hospital Anxiety and Depression Scale, Perception Survey
Study: NCT02046720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol induced sedation
Description: Propofol was administered using a commercially available target-controlled infusion with an incorporated pharmacokinetic model developed by Schnider (Base Primea , Fresenius-Kabi, Brezins, FRANCE)12. The initial effect-site target concentration of propofol (0.5 μg/ml) was incremented by 0.5 μg/ml every 5 minutes to ensure equilibration between plasma concentration and effect site, until loss of eyelash reflex. From the beginning of infusion until LOER patients received no other agent besides propofol for the duration of the trial.~The BIS index was compared between a young population (18 to 64 years old) and an elderly population (65 and more)
Study: NCT00940329

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Roflumilast
Description: Treatment A (500 μg/d roflumilast from day 2 to day 18 and 48 μg/d formoterol from day 12 to day 18)
Study: NCT03464409

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Semi-structured interview
Description: Semi-structured interviews to be conducted by a study team member.
Study: NCT00940329

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Roflumilast
Description: Treatment B (48 μg/d formoterol from day 2 to day 18 and 500 μg/d roflumilast from day 9 to day 18)
Study: NCT04196569

Intervention type: DEVICE
Intervention: Alcon Trifocal and Trifocal Toric Intraocular Lenses
Description: Panoptix Model #TFAT00 for the UV Absorbing Trifocal IOL. Torics:~TFAT30, TFAT40, TFAT50, TFAT60
Study: NCT03389503

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radial approach
Description: Approach site for coronary angiography and coronary intervention

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radial approach
Description: Approach site for coronary angiography and coronary intervention
Study: NCT00747110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide
Description: 3x 3mg budesonide capsules once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mesalazine
Description: 3x 1000mg mesalazine onc daily
Study: NCT03504527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triple combinations
Description: inhaled budesonide(160ug,bid),formotero(4.5ug,bid) and tiotropium bromide(18μg,qd)
Study: NCT03464409

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Semi-structured interview
Description: Semi-structured interviews to be conducted by a study team member.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Semi-structured interview
Description: Semi-structured interviews to be conducted by a study team member.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Cord Independence Measure (SCIM-SR)
Description: The Spinal Cord Independence Measure - Self Report (SCIM-SR) is a self-report instrument for assessing functional independence of persons with spinal cord injury.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Cord Independence Measure (SCIM-SR)
Description: The Spinal Cord Independence Measure - Self Report (SCIM-SR) is a self-report instrument for assessing functional independence of persons with spinal cord injury.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Cord Independence Measure (SCIM-SR)
Description: The Spinal Cord Independence Measure - Self Report (SCIM-SR) is a self-report instrument for assessing functional independence of persons with spinal cord injury.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SF-36
Description: A health-related quality of life (QoL) self-reported survey.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SF-36
Description: A health-related quality of life (QoL) self-reported survey.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SF-36
Description: A health-related quality of life (QoL) self-reported survey.
Study: NCT02055287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY03004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY03004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY03004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY03004
Study: NCT03852017

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audio Program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Audio Program
Study: NCT01695616

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active drug
Study: NCT01381965

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vitreous surgery for macular hole
Description: Vitreous surgery for macular hole
Study: NCT00725283

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI)
Description: Intramuscular administration
Study: NCT02773147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyanocobalamin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridoxine